REFERENCES
- Denis L. A new non-steroidal anti-androgen. In: Murphy GP, Khoury S. eds. Therapeutic progress in urological cancers. New York: Alan R. Liss, 189; 95–103.
- Fawcett DW. A textbook of histology. Philadelphia: WB Saunders, 1986.
- Furr BJA. The case for pure antiandrogens. In: Furr BJA, Denis L, eds. Clinical oncology, Vol. 2, No. 3, Prostatic cancer. London: Balliere Tindall, 1988; 581–590.
- Katchen B, Buxbaum S. Disposition of a new, nonsteroid, anti-androgen, alpha, alpha, alpha-trifluoro-2-methyl-4'-nitro-m-propionotoluidide (Flutamide), in men following a single oral 200 mg dose. J Clin Endcrinol Met 1975; 41: 373–379.
- Liao S, Howell DK, Chang TM. Action of a nonsteroidal anti-androgen, Flutamide, on the receptor binding and nuclear retention of 5 alpha-dihydrotestosterone in rat ventral prostate. Endocrinology 1974; 94: 1205–1209.
- Mostofi FK, PriceJr EB. Tumours of the male genital system. In: Atlas of tumour pathology. Second series. Washington: Armed Forces Institute of Pathology, 1973.
- Murphy WM. Urological pathology. Philadelphia: WB Saunders, 1989.
- Neumann F, Bormacher K, Habenicht UF, Radlmaier A. Principles of androgen deprivation. In: Schrôder FC, ed. EORTC genitourinary group. Monograph 8: Treatment of prostatic cancer—facts and controversies. New York: Wiley-Liss, 190; 75–83.
- Schacher A. Wirkung von verschiedenen Verbindungen mit antiandrogener Eigenschaft auf die Wechselwirkung zwischen Hypothalamus, Hypophyse und Hoden. Thesis, Berlin, 1981.